Evidence map›Paper›PMID 34140500›Full record

ArticleNature communications2021

Combining machine learning and nanopore construction creates an artificial intelligence nanopore for coronavirus detection.

Masateru Taniguchi, Shohei Minami, Chikako Ono, Rina Hamajima, Ayumi Morimura, Shigeto Hamaguchi, Yukihiro Akeda, Yuta Kanai, Takeshi Kobayashi, Wataru Kamitani and 12 more

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Metrology of Nanoscale Objects Using Nanopores.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  9. Review
  10. Designing the Next Generation of Biomaterials through Nanoengineering.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Detection of protein oligomers with nanopores.Nature reviews. Chemistry · 2025
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Masateru TaniguchiThe Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka, Japan. taniguti@sanken.osaka-u.ac.jp.ORCID 0000-0002-0338-8755
Shohei MinamiResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Chikako OnoResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Rina HamajimaResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Ayumi MorimuraGraduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Shigeto HamaguchiGraduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Yukihiro AkedaResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Yuta KanaiResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Takeshi KobayashiResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Wataru KamitaniGraduate School of Medicine, Gunma University, Maebashi, Gunma, Japan.
Yutaka TeradaCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
Koichiro SuzukiThe Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
Nobuaki HatoriThe Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
Yoshiaki YamagishiGraduate School of Medicine, Osaka University, Suita, Osaka, Japan.ORCID 0000-0002-9163-787X
Nobuei WashizuADVANTEST Corporation, Kazo, Saitama, Japan.
Hiroyasu TakeiAipore Inc., Shibuya, Tokyo, Japan.
Osamu SakamotoAipore Inc., Shibuya, Tokyo, Japan.
Norihiko NaonoAipore Inc., Shibuya, Tokyo, Japan.
Kenji TatematsuThe Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka, Japan.
Takashi WashioThe Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka, Japan.
Yoshiharu MatsuuraResearch Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. matsuura@biken.osaka-u.ac.jp.ORCID 0000-0001-9091-8285
Kazunori TomonoGraduate School of Medicine, Osaka University, Suita, Osaka, Japan. tomono@hp-infect.med.osaka-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput, high-accuracy detection of emerging viruses allows for the control of disease outbreaks. Currently, reverse transcription-polymerase chain reaction (RT-PCR) is currently the most-widely used technology to diagnose the presence of SARS-CoV-2. However, RT-PCR requires the extraction of viral RNA from clinical specimens to obtain high sensitivity. Here, we report a method for detecting novel coronaviruses with high sensitivity by using nanopores together with artificial intelligence, a relatively simple procedure that does not require RNA extraction. Our final platform, which we call the artificially intelligent nanopore, consists of machine learning software on a server, a portable high-speed and high-precision current measuring instrument, and scalable, cost-effective semiconducting nanopore modules. We show that artificially intelligent nanopores are successful in accurately identifying four types of coronaviruses similar in size, HCoV-229E, SARS-CoV, MERS-CoV, and SARS-CoV-2. Detection of SARS-CoV-2 in saliva specimen is achieved with a sensitivity of 90% and specificity of 96% with a 5-minute measurement.

Indexed as

Artificial IntelligenceMachine LearningNanoporesCoronavirus 229E, HumanCOVID-19 Nucleic Acid TestingEquipment DesignHumansLimit of DetectionMiddle East Respiratory Syndrome CoronavirusNanoparticlesPolymerase Chain ReactionSalivaSARS-CoV-2Sensitivity and SpecificitySoftware

Identifiers

PMID34140500
PMCPMC8211865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.